Contact: [email protected]
* Studie on hold of geen beschikbare plaatsen
| Title | Tumor type | Line | Study information |
|---|---|---|---|
| Mountaineer-03 (SGNTUC-029) | CRC | 1L | Tucatinib+trastuzumab + mFOLFOX6 vs. mFOLFOX6 +/- bevacizumab/cetuximab in HER2+, RAS wt CRC |
| 61186372COR3001 (OrigAMI-2) | Left-sided CRC | 1L | Amivantamab vs cetuximab + folfox of folfiri |
| 61186372COR3002 (OrigAMI-3) | CRC | >1L | Amivantamab vs cetux/beva + folfiri rando 1:1 |
| CA266-0003* (ROSETTA CRC-203) | mCRC | 1L | Pumitamig vs beva + chemo |
| CA240-0030 * (MountainTAP30) | Pancreas | 1L | BMS-986504 with nab-p/gem vs placebo with nab-p/gem |
| Nalpac | Pancreas | 2L | Naliri vs Nalirinox. PD after 1st line gemcitabine mono or gem/abraxane |
| Stereopac | Pancreas | Neoadjuvant | Preop mFOLFIRINOX (or gem/NabP) +/- SBRT in borderline resectable |
| Torpedo | Pancreas | Neoadjuvant | Preop mFOLFIRINOX (or gem/NabP) +/- SBRT in locally advanced |
| JZP598-302 | BTC | 1L | zanidatamab + gem/cis + PD-1/L1 (=SOC) vs SOC |
| D781PC000001 (Destiny BTC01) | BTC | 1L | T-DXd + rilvegostomig of T-DXd mono vs gemcitabine + cisplatin + durvalumab |
| D702NC00001 Artemide BTC 02 | BTC | 1L | Rilvegostomig vs durvalumab + gemcitabine/ cisplatin |
| D702AC00001 (ARTEMIDE-Gastric01) | Gastric + GEJ | 1L | Rilvegostomig + Fluoropyrimidine + T-Dxd vs trastuzumab + chemo + pembrolizumab vs Rilvegostomig + chemo + T-Dxd |
| RAINSPOT | Gastric + GEJ | 2L | Zolbetuximab+Paclitaxel+Ramucirumab |
| Bayer 22262 (Bantam-01) | HCC | Depending on available slots | Actinium-225 labelled anti-GPC3 antibody + BAY 3547922 |
| LEVEL trial | somatostatin positive NET lung en Thymus | <3L | Peptide receptor radionuclide with 177Lu-edotreotide vs everolimus |
| DS7300-202 (IDeate-Esophageal01) | unresectable or m+ ESCC | 2L | I-DXd vs chemo (paclitaxel, docetaxel, irinotecan HCl) |
| SAFIR-ABC10 | BTC | 1L (maintenance) | Matched targeted maintenance therapy vs continuation of 1L-SoC |
Research Team